Quest Diagnostics Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Quest Diagnostics Inc trades at $230.82 (market cap $25.48B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.7 (market cap $7.77B). The key difference: Quest Diagnostics Inc is far larger — about 3.3× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| DGX | PDBC | |
|---|---|---|
Market Cap | $25.48B | $7.77B |
Volume | 941,866 | 6,100,303 |
Sector | Health | — |
52-Week High | $247.45 | $20.10 |
52-Week Low | $173.49 | $13.16 |
Typical Hold Time | 56 Days | 56 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.66, up 1.29% with strong bullish momentum from moving averages. The ETF has delivered exceptional performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows significant position increases despite a 215% surge in short interest in September.
The outlook remains positive given strong commodity trends and defensive positioning benefits, though elevated short interest and RSI levels near overbought territory suggest potential near-term volatility. Commodity exposure provides inflation hedging advantages but remains sensitive to geopolitical developments and global economic conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →